Young women, late diagnoses: Memorial Sloan Kettering Cancer Center urges greater awareness of ovarian cancer across the Gulf

New research shows how inherited genetics vary across populations and can influence which cancers a woman develops and how they respond to treatment

ABU DHABI, DUBAI, RIYADH, DOHA, 8 May 2026. On World Ovarian Cancer Day, Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer centers, is urging women and families across the Gulf region to prioritize early evaluation for ovarian cancer. In the Gulf, women tend to be diagnosed with cancer at a younger age than in Western countries, with peak female cancer incidence falling between 40 and 60 years, compared to a global median ovarian cancer diagnosis age of 63.[1] For a disease where catching it early can mean the difference between a strong chance of survival and a slim one, that earlier window matters enormously.

Ovarian cancer is one of the hardest cancers to detect early. Its symptoms, including bloating, pelvic discomfort, and changes in appetite, are easily attributed to other causes. Globally, around two-thirds of cases are diagnosed at stage III or IV, when the disease has already spread. As specialist gynaecologic oncology services continue to develop across the Gulf, access to internationally recognised centres remains an important option for patients with complex or advanced disease.

“When ovarian cancer is caught early, survival rates are dramatically higher,” said Nadeem R. Abu-Rustum, Chief of the Gynecologic Service at MSK. “The challenge is building the awareness and access that make early detection possible, and that starts with women feeling confident to raise their concerns with a doctor.”

New research shows how inherited genetics shape tumor genomes

MSK oncologist Dr. Jian Carrot-Zhang

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, MSK oncologist Dr. Jian Carrot-Zhang presented findings from a large-scale multi-ancestry study showing that the genes you are born with can influence how a cancer develops and behaves and that these patterns differ across populations. Research from the Gulf region has found that genetic testing for these variants is not yet routine practice across the region, despite its potential to guide personalized treatment.[2]

“Understanding how inherited genetics influence tumour development could open new doors for more personalized cancer care,” said Dr. Carrot-Zhang. “Since many of the changes we studied are already used to guide treatment decisions, this research has immediate practical implications for patients and their oncologists.”

MSK’s gynaecologic oncology programme brings together surgery, chemotherapy, targeted therapy, immunotherapy, and genetic counselling under one roof. For patients travelling from the Gulf, whether seeking a second opinion or treatment for advanced or complex disease, the Center’s international patient services team supports the full journey, from first consultation to follow-up care.

MSK encourages women, particularly those with a family history of ovarian or breast cancer, to speak with a healthcare provider if any symptoms persist for more than two to three weeks.

### 

About Memorial Sloan Kettering Cancer Center (MSK)

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years and ranked as the best hospital in the world for oncology according to Newsweek’s World’s Best Specialized Hospitals 2026 list. http://www.mskcc.org.

---

[1] Cancer Burden in the Abu Dhabi Population, medRxiv, January 2025; Ovarian Cancer Statistics, OCRA

[2] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study, PMC / PubMed, December 2021.